Enesi Pharma

Enesi Pharma is developing next-generation vaccination products targeting infectious diseases and emergent threat pathogens enabled by its ImplaVax® technologies. These diseases affect millions of people around the world. We work in partnership with global companies, government agencies, leading academic institutions and non-governmental organisations with the goal of making a material and lasting positive impact on global health. Our award-winning ImplaVax®-enabled vaccination products leverage our innovative unit solid-dose formulation and needle-free delivery technologies and are applicable across all vaccine formats. ImplaVax® products are designed to enhance the immune response and offer significant benefits for patients, care givers, healthcare professionals and payers through enhanced effectiveness, safety, ease of use, reliability and stability, coupled with a strong subject preference over administration using needle and syringe. They do not require reconstitution prior to use, and each dose is a useful dose with no wastage possible. They can be administered with minimal training and are also rapidly deployable while eliminating the need for cold-chain storage. Our pipeline targets a range of common and emerging infectious diseases, inflammatory diseases and allergies, and has been established through collaborations with world-class organisations, including BARDA DRIVe*, the Bill & Melinda Gates Foundation, Innovate UK, the University of Oxford, the Walter Reed Army Institute of Research (WRAIR), Imperial College London and the University of Adelaide. We are also advancing a number of collaborations with leading organisations in animal health, including The Pirbright Institute and the UK's Animal and Plant Agency (APHA). Enesi Pharma's experienced leadership team has a proven track record in the successful development and commercialisation of innovative products delivering high value outcomes for all stakeholders and is supported by a world-renowned Scientific Advisory Board. *This project has been funded in whole or in part with US Federal funds from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, DRIVe, under Contract No. 75A50119C00032.